Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Details for Australian Patent Application No. 2007281684 (hide)

Owner PDL BioPharma, Inc. Dana-Farber Cancer Institute, Inc.

Inventors Tai, Yu-Tzu; Anderson, Kenneth C.; Afar, Daniel

Agent Davies Collison Cave

Pub. Number AU-A-2007281684

PCT Pub. Number WO2008/019378

Priority 60/836,185 07.08.06 US; 60/944,262 15.06.07 US

Filing date 7 August 2007

Wipo publication date 14 February 2008

International Classifications

A61K 31/454 (2006.01)

A61K 31/69 (2006.01) - Boron compounds

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

5 March 2009 PCT application entered the National Phase

  PCT publication WO2008/019378 Priority application(s): WO2008/019378

22 October 2009 Assignment before Grant

  PDL BioPharma, Inc.; Dana-Farber Cancer Institute, Inc. The application has been assigned to Dana-Farber Cancer Institute, Inc.; Facet Biotech Corporation

3 February 2011 Alteration of Name

  The name of the applicant has been altered to Dana-Farber Cancer Institute, Inc.; Abbott Biotherapeutics Corp. Amendments

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007281686-System and method for providing hardware virtualization in a virtual machine environment

2007281682-Compositions and methods using antiCS1 antibodies to treat multiple myeloma